Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Phase 1
- Conditions
- DiarrheaMedullary Thyroid Cancer
- Interventions
- Drug: CASAD
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Salient Pharmaceuticals Incorporated
- Target Recruit Count
- 10
- Registration Number
- NCT01739634
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection
Phase 2
Terminated
- Conditions
- Diarrhoea, Clostridium Difficile
- Interventions
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- Salient Pharmaceuticals Incorporated
- Target Recruit Count
- 2
- Registration Number
- NCT01570634
- Locations
- 🇺🇸
Scott & White Memorial Hospital, Temple, Texas, United States
News
No news found